duloxetine + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urinary Stress Incontinence
Conditions
Urinary Stress Incontinence
Trial Timeline
Oct 1, 2001 → Apr 1, 2006
NCT ID
NCT00190567About duloxetine + Placebo
duloxetine + Placebo is a phase 2 stage product being developed by Eli Lilly for Urinary Stress Incontinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00190567. Target conditions include Urinary Stress Incontinence.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931475 | Phase 3 | Completed |
| NCT01451606 | Approved | Terminated |
| NCT01226511 | Phase 3 | Completed |
| NCT01179672 | Phase 3 | Completed |
| NCT01237587 | Phase 3 | Completed |
| NCT01118780 | Approved | Completed |
| NCT01070329 | Approved | Completed |
| NCT01000805 | Approved | Completed |
| NCT01018680 | Phase 3 | Completed |
| NCT00965081 | Approved | Completed |
| NCT00803361 | Phase 3 | Completed |
| NCT00767806 | Phase 3 | Completed |
| NCT00433290 | Phase 3 | Completed |
| NCT00424593 | Phase 3 | Completed |
| NCT00457730 | Phase 2/3 | Completed |
| NCT00408876 | Phase 3 | Completed |
| NCT00408421 | Phase 3 | Completed |
| NCT00607789 | Approved | Completed |
| NCT00375973 | Phase 2/3 | Completed |
| NCT00233025 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Stress Incontinence